“Fed will push us into recession” Economist
Post# of 6680
(Total Views: 123)
Posted On: 10/24/2022 10:15:10 AM
“Fed will push us into recession”
Economists have been raising their doubts in the FED’s capability in handling the rising inflation rate which is looking to fall of the edge into a oblivion recession.
As shared by economist Mohamed A. El-Erian “It is, unfortunately, uncomfortably possible that the Fed is going to slam on the brakes and push us into recession,” during his interview on Yahoo Finance Live in an online interview.
El-Erian’s also remarks that the Fed’s move last week in raising interest rates by 75 basis points (the most aggresive hike in decades) has made Wall Street strategist in notion for an economic slowdown.
The US Central bank was too late in acknowledging that inflation will become a problem and was not quick enough to reacting to the surging prices thus losing credibility in the eyes of wall street and also investors.
Losing credibility in the FED will lead to people doubting its projects, consequently leaving the people with skepticism and distrust towards the FED.
[https://finance.yahoo.com/news/its-uncomfortably-possible-fed-may-push-us-into-recession-economist-164054602.html](https://finance.yahoo.com/news/its-uncomfortably-possible-fed-may-push-us-into-recession-economist-164054602.html)
Investors are suggested to rotate their portfolio into defensive sectors which are known to be resilient towards times of economic recession ie. Healthcare, F&B, Utilities and REITs.
Regencell Bioscience Holdings , ticker $RGC is a bioscience healthcare company which had been listed in the NASDAQ market in USA. The company’s business is predominantly in the Research & Development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of the coronavirus disease esp. COVID-19, for which there are unmet holistic medical needs in the global market.
Since its inception into IPO last year July, the stock has seen a 300% rise. The stock has a Outstanding Shares of 13.01M and Floating Shares of 1.44M. The CEO is currently holding >80% of the company shares.
Economists have been raising their doubts in the FED’s capability in handling the rising inflation rate which is looking to fall of the edge into a oblivion recession.
As shared by economist Mohamed A. El-Erian “It is, unfortunately, uncomfortably possible that the Fed is going to slam on the brakes and push us into recession,” during his interview on Yahoo Finance Live in an online interview.
El-Erian’s also remarks that the Fed’s move last week in raising interest rates by 75 basis points (the most aggresive hike in decades) has made Wall Street strategist in notion for an economic slowdown.
The US Central bank was too late in acknowledging that inflation will become a problem and was not quick enough to reacting to the surging prices thus losing credibility in the eyes of wall street and also investors.
Losing credibility in the FED will lead to people doubting its projects, consequently leaving the people with skepticism and distrust towards the FED.
[https://finance.yahoo.com/news/its-uncomfortably-possible-fed-may-push-us-into-recession-economist-164054602.html](https://finance.yahoo.com/news/its-uncomfortably-possible-fed-may-push-us-into-recession-economist-164054602.html)
Investors are suggested to rotate their portfolio into defensive sectors which are known to be resilient towards times of economic recession ie. Healthcare, F&B, Utilities and REITs.
Regencell Bioscience Holdings , ticker $RGC is a bioscience healthcare company which had been listed in the NASDAQ market in USA. The company’s business is predominantly in the Research & Development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of the coronavirus disease esp. COVID-19, for which there are unmet holistic medical needs in the global market.
Since its inception into IPO last year July, the stock has seen a 300% rise. The stock has a Outstanding Shares of 13.01M and Floating Shares of 1.44M. The CEO is currently holding >80% of the company shares.
(0)
(0)